Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance.
We examined the role of CD40/CD40L interactions on the development of experimental autoimmune uveoretinitis (EAU), a cell-mediated, Th1-driven autoimmune disease that serves as a model for autoimmune uveitis in humans. EAU-susceptible B10.RIII mice immunized with the retinal autoantigen interphotoreceptor retinoid binding protein in CFA and treated with anti-CD40L Ab (MR1) had reduced incidence and severity of disease. Real-time PCR analysis revealed that the innate and adaptive responses of protected mice were reduced, without an obvious shift toward a Th2 cytokine profile. In contrast to some other reports, no evidence was found for regulatory cells in adoptive transfer experiments. To determine whether CD40L blockade resulted in long-term tolerance, mice protected by treatment with MR1 Ab were rechallenged for uveitis after circulating MR1 Ab levels dropped below the detection limit of ELISA. MR1-treated mice developed severe EAU and strong cellular responses to interphotoreceptor retinoid binding protein, comparable to those of control mice. These responses were higher than in mice that had not received the primary immunization concurrently with anti-CD40L treatment. We conclude that 1) CD40/CD40L interaction is required for EAU and its disruption prevents disease development; 2) CD40L blockade inhibits the innate response to immunization and reduces priming, but does not result in immune deviation; and 3) protection is dependent on persistence of anti-CD40L Abs, and long-term tolerance is not induced. Furthermore, immunological memory develops under cover of CD40L blockade causing enhanced responses upon rechallenge. Taken together, our data suggest that ongoing CD40/CD40L blockade might be required to maintain a therapeutic effect against uveitis.
Bagenstose
Lee M
LM
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Agarwal
Rajeev K
RK
Silver
Phyllis B
PB
Harlan
David M
DM
Hoffmann
Steven C
SC
Kampen
Robert L
RL
Chan
Chi-Chao
CC
Caspi
Rachel R
RR
D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D019013:CD40 Antigens / Q000378:metabolism*; D023201:CD40 Ligand / Q000378:metabolism*; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007114:Immunization; D007156:Immunologic Memory; D051379:Mice; D012173:Retinitis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D012177:Retinol-Binding Proteins / Q000276:immunology; D014605:Uveitis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D000099214:Retinol-Binding Proteins, Interstitial
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D023201:CD40 Ligand; D005136:Eye Proteins; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial